BioCardia CEO Peter Altman Buys 4,300 Shares (Open Market)

What Happened
Peter Altman, President, CEO and a director of BioCardia, reported two open-market purchases (code P) totaling 4,300 shares. On 2026-07-14 he acquired 2,800 shares at a weighted average price of $0.88 ($2,464), and on 2026-07-15 he acquired 1,500 shares at a weighted average price of $0.86 ($1,290). The combined value of the purchases is $3,754. These were straightforward purchases (often viewed by investors as a bullish signal), not sales or option exercises.

Key Details

• Transaction dates: 2026-07-14 (2,800 sh @ $0.88, $2,464) and 2026-07-15 (1,500 sh @ $0.86, $1,290). Total 4,300 shares for $3,754.
• Price details: each reported price is a weighted average; individual trades ranged $0.86–$0.89 (see footnotes F1, F2). The reporting person offered to provide per-trade breakdown on request.
• Transaction type: Open-market purchases (Form 4 code P).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing timeliness: Form 4 was filed on 2026-07-15 (the filing appears timely relative to the reported trades).

Context
These purchases are modest in dollar terms (under $4k total). For retail investors, insider buys can be informative, but small open-market purchases may reflect personal investment decisions rather than a material signal about company prospects. No option exercises, awards, gifts, or tax-withholding actions are reported in this filing.